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Abstract
Background: Abnormalities in lipid metabolism and transport are hallmarks in analbuminemic Nagase rats (NAR)
and humans. Triglyceridemia is nearly 3- to 5-fold higher in female NAR than in control Sprague-Dawley rats (SDR).
Also, NAR present with a severe plasma free fatty acid (FFA) deficit. There are conflicting results regarding the
mechanisms underlying NAR hypertriglyceridemia.
Objective: We aimed at investigating whether liver lipogenesis and triglyceride secretion rates into the plasma
contribute to the hypertriglyceridemia in NAR. We also studied whether heparin or albumin administration would
release the hypothesized lipolysis inhibition in NAR.
Methods: The incorporation of tritiated water into lipids and the linear accumulation rate of plasma triglycerides
after Triton WR1339 injection were the measures of liver lipogenesis and triglyceride secretion rates.
Results: Lipogenesis (596 ± 40 vs. 929 ± 124 μmol
3H2O/g/h) and triglyceride (4.25 ± 1.00 vs. 7.04 ± 1.68 mg/dL/
min) secretion rates were slower (P ≤ 0.05) in fasted NAR than in control SDR. The injection of either heparin or
albumin elicited an increase in NAR plasma FFA levels over time. FFA levels reached control levels 90 min after the
albumin administration, increasing from 0.36 ± 0.05 to 1.34 ± 0.16 mEq/L (P ≤ 0.05). These results indicate that the
lack of plasma albumin inhibits intravascular lipolysis and causes the FFA deficit observed in NAR.
Conclusion: NAR hepatic triglyceride synthesis and output do not contribute to NAR hypertriglyceridemia. We
propose that the lack of albumin diminishes intravascular lipolysis which reduces the plasma triglyceride removal
rate and explain both NAR hypertriglyceridemia and FFA deficiency.
Introduction
Albumin is the most abundant plasma protein in mam-
mals and plays an important role as a carrier for a variety
of molecules. Albumin possesses a high binding affinity
for certain divalent cations, bilirubin, free fatty acids
(FFA) and other molecules, including xenobiotics. Due to
its high abundance and low molecular weight in relation
to other major plasma proteins, albumin is responsible
for about 80% of the total plasma oncotic pressure [1].
Therefore, albumin is a key regulator of fluid distribution
between the plasma and interstitial compartments in
physiological conditions; although the absence of plasma
albumin can be well compensated by increased liver
secretion of other proteins which help to maintain nearly
normal plasma oncotic pressure [2]. Other less under-
stood functions may also be ascribed to albumin, since its
plasma depletion and redox modification have been
demonstrated in several pathological conditions [3-5].
Both humans and rats (Nagase rats, NAR) suffering
from congenital analbuminemia present with minor
clinical symptoms despite the ascribed roles of albumin
[6-8]. Abnormalities in fat storage and in lipid metabo-
lism and/or transport are hallmarks of analbuminemic
NAR and humans [9-15]. Plasma triglyceride (TG) levels
are 3- to 5-fold higher in female NAR than in control
Sprague-Dawley rats (SDR). A more severe dyslipidemia
in female NAR seems to be partially driven by estrogen
[13]. Compared to male, female NAR also develop more
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do not present a deficit in total plasma proteins [2]. In
analbuminemic plasma, very low density lipoprotein tri-
glycerides (VLDL-TG) accounts for the largest fraction
of total triglycerides [15]. Conversely, plasma FFA levels
are severely decreased in NAR compared to control
[14]. In addition, analbuminemic rats and human sub-
jects present with hypercholesterolemia [6,9,11,12]. This
lipemic phenotype predisposes the affected individuals
to a higher risk of developing cardiovascular disease,
while low levels of FFA may contribute to other meta-
bolic-related alterations, such as the fatigue experienced
by analbuminemic individuals [7,11,12,16].
Studies addressing the basis of hypertriglyceridemia in
NAR have shown conflicting results. Catanozzi et al.
[17] reported a faster triglyceride secretion rate from the
liver and a slightly faster VLDL-protein plasma clear-
ance rate. In contrast, others have demonstrated that
NAR present with a slower plasma clearance rate of
chylomicron-TG [16] or a similar clearance rate of
VLDL- and chylomicron-TG [18]. In addition, lower
post-heparin plasma lipoprotein lipase (LPL) activity has
been described in NAR [13,19]. Regarding the hepatic
production of triglycerides, Joles et al. [9] showed that
the liver lipogenesis rate is not different between NAR
and SDR. Therefore, no clear conclusions can be drawn
concerning the main metabolic processes contributing
to NAR hypertriglyceridemia. Differences in criteria for
animal group pairing (by body mass or by age), sex,
basal states (fasted vs. fed) and methodology may
account for these data discrepancies.
Despite the known roles of albumin as a FFA acceptor
and carrier [20], there are no data on the mechanism
underlining the low levels of plasma FFA found in NAR.
It is still unknown whether the FFA deficit is a conse-
quence of lipolysis inhibition, either directly by lower
LPL activity [13,19] or by a deficiency in plasma albumin,
or by both. Abnormalities, such as lower body mass and
adiposity [10] and the exercise and starvation intolerance
observed in NAR [21,22], seem consistent with a condi-
tion of lower FFA availability and flux into tissues [16,23].
In this work, we found that liver lipogenesis and hepatic
triglyceride output are decreased in fasted NAR compared
to control. We also show that the low levels of plasma FFA
are due to an inhibition of intravascular lipolysis caused by
an acceptor (albumin) deficiency in NAR. All together, our
data indicate that hepatic triglyceride production does not
contribute to NAR fasting hypertriglyceridemia.
Materials and methods
Animal housing and plasma variable assessments
NAR founders were kindly donated by Dr. Eder Quintão
from the Lipid Laboratory at the University of São Paulo
Medical School and were bred and maintained in the
animal facility of our department. The experiments were
approved by the Committee for Ethics in Animal Experi-
mentation at the University and are in accordance with
the Guide for the Care and Use of Laboratory Animals
published by the National Academy of Sciences. The rats
had free access to a standard laboratory rodent chow diet
(Nuvital CR1) and water. Female rats, 12-14 weeks old,
were housed at 22 ± 2°C on a 12 h light-dark cycle.
Unless otherwise stated, all the measurements were car-
ried out in female NAR after a 20-h fasting, and the
blood samples were taken from the tip of the tail. Trigly-
cerides (Roche Diagnostics), total cholesterol (Roche
Diagnostics), total proteins (Bradford, Sigma) and free
fatty acids (Wako Chemicals, Japan) were determined in
the plasma using enzymatic-colorimetric methods
according to the instructions of the manufacturers.
Total liver lipogenesis
The rate of total lipid synthesis was measured in vivo.
The rats were injected intraperitoneally with 20 mCi of
tritiated water (
3H2O) dissolved in an isotonic saline
solution as described previously [24]. One hour later,
blood samples were obtained from the tip of the tail
from anesthetized rats (ketamine 75 mg/kg and xylazine
10 mg/kg), and livers were excised, minced, and saponi-
fied; after which lipids were extracted with hexane [25].
Radioactivity in the lipid extract was measured in a Beta
Counter (LS6000 Beckman Instruments, California,
USA). The specific activity of
3H2O was measured in
the plasma in triplicate. The rate of total lipid synthesis
was calculated as μmol of
3H2O incorporated into the
lipids per gram of tissue in one hour (μmol/g/h).
Triglyceride secretion rate
The hepatic triglyceride secretion rate to the plasma was
measured after the administration of Tyloxapol WR1339
(Sigma), as described previously by Otway & Robinson
[26]. Briefly, rats were bled to obtain baseline plasma sam-
ples and then injected intravenously (tail vein) with Tylox-
apol WR1339 at a dose of 400 mg/kg (15% v/v solution in
saline). Blood samples (50 μL) were collected at 15, 30, 60,
and 90 min after the Tyloxapol WR1339 injection. Trigly-
ceride levels were measured in the plasma samples. The
slopes from the linear regression of the triglyceride con-
centrations vs. time curves were calculated (mg/dL/min).
Experiments were performed between 10:00 and 13:00 h.
Additional groups of overnight sucrose-fed (5% in drink-
ing water) female and male NAR were also subjected to
this experiment. These rats were fed with carbohydrate
only to avoid interference of absorbed fat.
Albumin- or heparin-stimulated in vivo lipolysis
Sodium heparin (Cristália, Brazil) and bovine serum albu-
min (globulin and fatty acid free, Sigma) were diluted in
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intraperitoneally) or with albumin (1.3 g/kg, intrave-
nously). Blood samples were taken before (0 min) and
after the injections (30 and 90 min). After blood plasma
was separated by centrifugation (4°C, 3000 g for 10 min),
plasma FFA levels were measured. FFA levels were also
measured in an aliquot of the injected albumin solution
but were not detected. In order to control for likely
changes in plasma volume due to the intravascular albu-
min injection (0.27 mL per 100 g), additional NAR and
SDR groups were injected with saline at the same volume.
The amount of injected albumin (1.3 g/kg) was expected
to elevate plasma albumin concentrations from nearly
zero to above 17 mg/mL in NAR [17]. As conducted in
females, the lipolysis induced by intravenous albumin
injection was also studied in fasting male NAR, but plasma
free glycerol levels, instead of plasma FFA, were measured
enzymatically (Sigma).
In vitro serum lipolysis
Blood samples from resting rats were taken without
anti-clogging agents and immediately centrifuged (4°C,
3000 g for 10 min) to separate the serum. Aliquots of
the serum (120 μL) were incubated with exogenous
albumin (final concentration of 30 mg/mL) or its vehicle
(saline) at 37°C for 10 min with continuous shaking. Ali-
quots (20 μL) were withdrawn and quickly frozen in
liquid nitrogen for later FFA analysis. Lipolysis was cal-
culated as an increase in FFA concentration between the
time points (zero to 10 min).
Statistical analysis
Data are represented as mean ± SD. Differences between
means were assessed by a Student’st - t e s to ro n e -o r
two-way analysis of variance (ANOVA) with repeated
measures. A one-way ANOVA was run within the NAR
albumin group to test for the effects of the albumin
injection (Figure 2A) because we compared the pre-and
post-injection values within this group only. The signifi-
cance level was set at P ≤ 0.05.
Results
The body and liver masses and the concentrations of the
plasma lipids and proteins from NAR and SDR are
shown in Table 1. As compared to SDR of the same
age, 12-14 week old female NAR exhibited lower body
and higher liver masses, a 5-fold increase in TG levels, a
2.6-fold increase in cholesterol levels, and one-third of
the FFA concentrations (P ≤ 0.05). Enlarged NAR livers
probably reflect hypertrophy to compensate for the
albumin deficiency, leading to additional synthesis and
secretion of other plasma proteins.
The liver lipogenesis rate (596 ± 40 vs. 929 ± 124
μmol
3H2O/g/h) and the hepatic TG secretion rate into
the plasma (4.25 ± 1.00 vs. 7.04 ± 1.68 mg/dL/min)
were significantly (P ≤ 0.05) reduced in the 20-h fasted
NAR compared to the SDR controls (Figure 1). In over-
night sucrose-fed female (n = 4 each group) and male
(n = 6 each group) rats, the hepatic TG secretion rates
into the plasma were not significantly different between
NAR and SDR: 5.27 ± 0.73 vs 6.08 ± 0.56 mg/dL/min
for females, and 2.95 ± 0.77 vs 3.67 ± 0.82 mg/dL/min
for males. Therefore, irrespective of feeding state and
sex, liver triglyceride output does not explain the higher
TG plasma levels in NAR.
Data from early in vitro studies with purified LPL
[20,27] showed that albumin allows lipolysis to proceed
by acting as a FFA acceptor. Here, we show that an
intravascular injection of albumin into NAR elicited an
almost linear increase in the plasma FFA levels over
time (Figure 2A). NAR plasma FFA levels increased 4-
fold from a baseline of 0.36 ± 0.05 to nearly the control
levels of 1.34 ± 0.16 mEq/L 90 min after the injection
(P ≤ 0.05) (Figure 2A). SDR and NAR groups were also
injected with saline to control for possible changes in
plasma volume, which actually did not cause significant
fluctuations in plasma FFA levels (Figure 2A). A heparin
injection, which is known to increase the plasma activity
of LPL [28], promptly increased (P ≤ 0.05) the plasma
FFA levels in NAR but had no effect on SDR (Figure
2B). The highest increase in plasma FFA levels in NAR
was observed 30 min after the heparin injection (from a
baseline of 0.52 ± 0.12 to 1.40 ± 0.41 mEq/L, P ≤ 0.05)
and decreased thereafter (Figure 2B). Despite the lack of
albumin acting as a FFA acceptor in NAR, the heparin
injection was effective in acutely increasing plasma FFA
levels, probably because lipoproteins can carry an addi-
tional load of FFA [29]. The lack of an observable effect
o fh e p a r i no nS D R ’s plasma FFA levels is probably due
Table 1 Body and liver masses and plasma lipid and
protein concentrations in analbuminemic (NAR) and
control (SDR) rats
SDR NAR
Body Mass
(g)
285.8 ± 24.8
N=9
216.4 ± 8.7*
N=9
Liver Mass
(g/100 g)
3.4 ± 0.2
N=9
5.5 ± 0.4*
N=9
Plasma Proteins
(g/L)
59.3 ± 8.0
N=4
55.7 ± 3.3
N=4
Triglycerides
(mg/dL)
62.2 ± 20.1
N=1 0
316.8 ± 99.8*
N=1 0
Cholesterol
(mg/dL)
72.6 ± 15.5
N=1 0
189.2 ± 22.8*
N=1 0
FFA
(mEq/L)
1.53 ± 0,22
N=8
0.48 ± 0,06*
N=8
Mean ± SD. *P ≤ 0.05 vs. SDR. Female Nagase rats (NAR) and Sprague-Dawley
rats (SDR) were paired by age (12 to 14 weeks old). Liver mass expressed as
gram per 100 g of total body mass. FFA: free fatty acids.
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teins) after the long fasting period.
The effect of exogenous albumin (final concentration of
30 mg/mL) on in vitro lipolysis was also studied. The
addition of albumin to NAR serum promoted a nearly 3-
fold stimulation in the amount of released FFA (Figure
3). The extent of lipolysis, taken as FFA accumulation
above the initial values in NAR serum, increased (P ≤
0.05) from 120.3 ± 21.1 (saline control) to 310.2 ± 51.5
uEq/L in the presence of exogenous albumin.
Since female NAR present with more prominent
abnormalities in lipid metabolism compared to male
NAR [12,30], we also investigated whether intravenous
albumin injection would stimulate plasma lipolysis in
fasted male NAR. Similarly to female NAR, plasma lipo-
lysis was stimulated in male NAR as indicated by a
2-fold increase (P ≤ 0.05) in plasma free glycerol levels
90 min after the intravenous injection of albumin (from
ap r e - i n j e c t i o nl e v e lo f1 25.0 ± 17.7 to 260.4 ± 31.3
umol/L at the 90
th min after the injection).
Discussion
Our results indicate that hypertriglyceridemia in analbu-
minemic rats does not occur as a result of increased
hepatic triglyceride synthesis and output (Figure 1).
Consequently, a slower removal rate of the plasma
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hypertriglyceridemia. Triglyceride removal from the cir-
culation by targeted tissues occurs after their breakdown
into glycerol and FFA [31]. Most of the FFA (~80%)
that are derived from the LPL-mediated lipolysis of
plasma triglyceride-rich lipoproteins are mixed within
the pool of albumin-bound FFA before their transport
into tissues [23,32]. Our data show that plasma lipolysis
is stimulated by the exogenous administration of albu-
min in NAR, both in vivo (Figure 2A) and in vitro
(Figure 3). These data support that the lack of albumin
limits LPL activity and thus, slows down the removal
rate of plasma triglyceride-rich lipoproteins.
Regarding the contribution of hepatic triglyceride pro-
duction our findings differ from previous studies that
reported this process is enhanced in fasted female NAR
[13] and in glucose-fed male NAR [17]. However, in
sucrose-fed NAR groups, our results are in accordance
w i t hd a t af r o mJ o l e se ta l .[ 9 ]t h a ts h o w e ds i m i l a rl i v e r
lipogenesis rates between fed NAR and controls. Some
discrepancies may be due to important differences in
study design. First, we paired the rat groups by age
(3-month old) and not by body mass as did Catanozzi et
al. [17]. It is noteworthy that NAR are lighter than SDR at
the same age. Second, the time of the day at which the
experiments were conducted must be considered, since
circadian rhythms are well known modifiers of sterol and
lipid biosynthesis. While we performed the metabolic stu-
dies in the morning from 10:00 to 13:00 h, Catanozi et al.
[17] evaluated TG secretion rates from 17:00 to 19:00 h.
Third, fasting period and/or type of diet prior to the
experiments could also interfere in the results. Thus,
based on our findings one can conclude that, either during
fasting or fed states, hepatic triglyceride production does
not contribute to NAR hypertriglyceridemia. However,
since we measured liver lipogenesis only, we may not
exclude that extra-hepatic lipogenesis may contribute to
NAR hyperlipidemia as previously shown by Joles et al. [9].
A plasma FFA deficit (Table 1) has long been
described in NAR [14] and is also observed in analbumi-
nemic humans [7]. However, its physiological basis has
never been experimentally addressed. Our attempts to
stimulate plasma lipolysis, either by releasing the
hypothesized lipolysis inhibition (albumin injection) or
by increasing plasma LPL activity (heparin injection),
caused a significant increase in plasma FFA levels in
NAR, although only albumin induced a virtually com-
plete correction of the NAR plasma FFA deficit (Figure
2A). The fast rise in plasma FFA levels induced by the
injection of heparin in NAR (Figure 2B) reveals that the
restraint on intravascular lipolysis is not due to defective
LPL activity. Therefore, the metabolic machinery
involved in plasma triglyceride breakdown and FFA
release is not severely compromised in NAR and the
plasma FFA deficit reflects an impaired lipolysis due
mainly to a lack of plasma albumin as an acceptor.
However, since lower LPL activity was reported in NAR
parametrial adipose and heart tissues [10,19], it is possi-
ble that the lower tissue-specific LPL may constitute
another restraint for FFA flux into the NAR tissues [23].
Previous in vitro enzymatic studies using purified LPL
clearly demonstrated that albumin acts as a FFA acceptor
and allows lipolysis to proceed [20,27]. Yet, this funda-
mental role of albumin in the control of lipolysis was not
known to operate in vivo. The present results (Figure 2A)
expand these previous in vitro findings of albumin play-
ing a permissive role in intravascular lipolysis. To avoid
any misinterpretation between albumin having a FFA
sparing effect or stimulating lipolysis, we used an in vitro
setup to assess the effects of exogenous albumin on the
NAR serum lipolysis rate (Figure 3). This result clearly
indicates that albumin is affecting lipolysis, i.e. stimulat-
ing the appearance of FFA in NAR plasma.
In conclusion, although NAR present with marked
liver hypertrophy, the hepatic triglyceride synthesis and
output rates do not contribute to the analbuminemic
hypertriglyceridemia. Instead, an impaired triglyceride
removal from the circulation may cause this alteration.
It is proposed that a lack of plasma albumin to act as a
FFA acceptor inhibits the intravascular lipolysis rate,
which in turn hampers plasma triglyceride breakdown
and its plasma removal.
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